Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Daliresp
Synonyms :
Class :
Phosphodiesterase-4 Enzyme Inhibitors
Brand Name :
Daliresp
Synonyms :
Class :
Phosphodiesterase-4 Enzyme Inhibitors
Dosage forms & Strengths:Â
Adult:Â
Tablet:Â
250 mcgÂ
500 mcgÂ
Chronic Obstructive Pulmonary Disease (COPD)Â
500
mcg
Tablet
Orally 
once a day
4
weeks
Safety and efficacy are not seen in pediatricsÂ
Acute Hypercapnia Secondary To COPDÂ
Safety and efficacy are not seen in pediatrics
When nafcillin combines with roflumilast, nafcillin will decrease the effect of action of roflumilast by affecting enzyme CYP3A4 metabolism.
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
may enhance the adverse/toxic effect of alprostadil
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
bunazosin (Not available in the United States)
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
alpha1-Blockers may enhance the hypotensive effect of phosphodiesterase 5 Inhibitors
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
It may enhance the risk of adverse effects when combined with Platelets inhibitors
It may enhance the risk of adverse effects when combined with Platelets inhibitors
It may enhance the risk of adverse effects when combined with Platelets inhibitors
It may enhance the risk of adverse effects when combined with Platelets inhibitors
It may enhance the risk of adverse effects when combined with Platelets inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet Inhibitors
dexchlorpheniramine, dextromethorphan, and phenylephrine
It may enhance the risk of adverse effects when combined with platelet Inhibitors
It may enhance the risk of adverse effects when combined with platelet inhibitors
It may enhance the risk of adverse effects when combined with platelet inhibitors
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
it increases the concentration of active metabolites of roflumilast in the serum
it increases the concentration of roflumilast in the serum
it increases the concentration of active metabolites of roflumilast-containing products in the serum
products containing roflumilast increase the effect of hypotension of riociguat
it decreases the concentration of products containing roflumilast in the serum
it increases the concentration of products containing roflumilast in the serum
sapropterin may increase the hypotensive effect of phosphodiesterase 5 inhibitors
may increase the hypotensive effect of Blood Pressure Lowering Agents
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
It may enhance the risk of adverse effects when combined with general anesthesia
1-10%:Â
Diarrhea Â
Weight loss Â
Nausea Â
Headache Â
Back pain Â
Insomnia Â
Decreased appetite Â
DizzinessÂ
Frequency not defined:Â
SuicidalityÂ
Roflumilast is contraindicated in patients hypersensitive to the formulation’s active ingredient and other excipients.Â
Pregnancy consideration:Â Â
Data is not available regarding the use of drug during pregnancy.Â
Breastfeeding warnings:Â Â
Avoid using the drug during lactation.Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: roflumilastÂ
Pronounced: rof-lu-mih-lastÂ
Why do we use roflumilast?Â
Roflumilast belongs to the category of Phosphodiesterase-4 Enzyme Inhibitors. It is used to treat Chronic Obstructive Pulmonary Disease.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
